Review



yes1 recombinant human protein  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Thermo Fisher yes1 recombinant human protein
    ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or <t>Yes1</t> plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.
    Yes1 Recombinant Human Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yes1+recombinant+human+protein/pmc04799362-192-0-7
    Average 86 stars, based on 1 article reviews
    yes1 recombinant human protein - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "A phosphotyrosine switch regulates organic cation transporters"

    Article Title: A phosphotyrosine switch regulates organic cation transporters

    Journal: Nature Communications

    doi: 10.1038/ncomms10880

    ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or Yes1 plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.
    Figure Legend Snippet: ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or Yes1 plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.

    Techniques Used: Transfection, Incubation, Functional Assay, Plasmid Preparation, Immunoprecipitation

    ( a ) Schematic representation of Yes1 protein (upper panel) showing the SH3 domain. The lower panel shows the putative proline-rich SH3 binding sequence in OCT2. ( b ) Endogenous Yes1 was immunoprecipitated from Hela-Vector and Hela-OCT2 cell lysates using a mouse anti-Yes1 antibody, followed by western blot analysis with rabbit anti-FLAG and Yes1 antibodies. ( c ) Plasmids for OCT2 mutants were transiently transfected into Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM) or [ 14 C]-metformin (50 μM). The uptake levels were normalized to protein concentration in each group. The graph represents relative OCT2 function (TEA or metformin uptake) as compared to wild-type OCT2 transfected group. * indicates statistically significant as compared with wild-type group ( P <0.05, Student's t -test). ( d ) Hela cells were transiently transfected with indicated FLAG-tagged OCT2 constructs, followed by immunopreicipation with anti-FLAG antibodies and western blot analysis by FLAG and phosphotyrosine antibodies. ( e ) Proposed model of Yes1 and OCT2 interaction. ( f ) Plasmids for OCT1 and OCT3 mutants were transiently transfected in Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM). The uptake levels were normalized to protein concentration and the graph represents relative OCT2 function (TEA uptake) as compared with respective wild-type group. * indicates statistically significant as compared to wild-type group ( P <0.05, Student's t -test). All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.
    Figure Legend Snippet: ( a ) Schematic representation of Yes1 protein (upper panel) showing the SH3 domain. The lower panel shows the putative proline-rich SH3 binding sequence in OCT2. ( b ) Endogenous Yes1 was immunoprecipitated from Hela-Vector and Hela-OCT2 cell lysates using a mouse anti-Yes1 antibody, followed by western blot analysis with rabbit anti-FLAG and Yes1 antibodies. ( c ) Plasmids for OCT2 mutants were transiently transfected into Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM) or [ 14 C]-metformin (50 μM). The uptake levels were normalized to protein concentration in each group. The graph represents relative OCT2 function (TEA or metformin uptake) as compared to wild-type OCT2 transfected group. * indicates statistically significant as compared with wild-type group ( P <0.05, Student's t -test). ( d ) Hela cells were transiently transfected with indicated FLAG-tagged OCT2 constructs, followed by immunopreicipation with anti-FLAG antibodies and western blot analysis by FLAG and phosphotyrosine antibodies. ( e ) Proposed model of Yes1 and OCT2 interaction. ( f ) Plasmids for OCT1 and OCT3 mutants were transiently transfected in Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM). The uptake levels were normalized to protein concentration and the graph represents relative OCT2 function (TEA uptake) as compared with respective wild-type group. * indicates statistically significant as compared to wild-type group ( P <0.05, Student's t -test). All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Techniques Used: Binding Assay, Sequencing, Immunoprecipitation, Plasmid Preparation, Western Blot, Transfection, Protein Concentration, Construct

    ( a ) Wild-type FVB mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, the mice were euthanized and the kidneys were collected. Kidney tissue lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. ( b ) Male FVB mice were injected with dasatinib (15 mg kg −1 ) followed by pharmacokinetic analysis of dasatinib levels in the plasma. ( c ) Wild-type and Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later they were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.), followed by plasma collection at 5 min. The graph represents plasma TEA levels from n =5 mice per group. * indicates statistically significant as compared with wild-type vehicle group ( P <0.05, Student's t -test). ( d ) Isolated renal tubules were coincubated with dasatinib in the presence of the OCT2 substrate ASP (30 min), and relative uptake was measured compared with control group. ( e ) Wild-type FVB mice were injected with either control or Yes1 siRNA by hydrodynamic tail-vein injection (25 μg in 0.5 ml of PBS). Three days later, the mice were injected i.v. with a 0.2 mg kg −1 dose of [ 14 C]-TEA, and plasma levels of TEA were measured at 5 min ( n =5 mice per group). Kidneys were also collected to determine Yes1 knockdown. ( f ) Wild-type and Yes1 −/− mice ( n =5) were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.) and plasma levels of TEA were measured at 5 min. ( g ) Kidney tissue lysates from wild-type and Yes1 −/− were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.
    Figure Legend Snippet: ( a ) Wild-type FVB mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, the mice were euthanized and the kidneys were collected. Kidney tissue lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. ( b ) Male FVB mice were injected with dasatinib (15 mg kg −1 ) followed by pharmacokinetic analysis of dasatinib levels in the plasma. ( c ) Wild-type and Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later they were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.), followed by plasma collection at 5 min. The graph represents plasma TEA levels from n =5 mice per group. * indicates statistically significant as compared with wild-type vehicle group ( P <0.05, Student's t -test). ( d ) Isolated renal tubules were coincubated with dasatinib in the presence of the OCT2 substrate ASP (30 min), and relative uptake was measured compared with control group. ( e ) Wild-type FVB mice were injected with either control or Yes1 siRNA by hydrodynamic tail-vein injection (25 μg in 0.5 ml of PBS). Three days later, the mice were injected i.v. with a 0.2 mg kg −1 dose of [ 14 C]-TEA, and plasma levels of TEA were measured at 5 min ( n =5 mice per group). Kidneys were also collected to determine Yes1 knockdown. ( f ) Wild-type and Yes1 −/− mice ( n =5) were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.) and plasma levels of TEA were measured at 5 min. ( g ) Kidney tissue lysates from wild-type and Yes1 −/− were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Techniques Used: Injection, Western Blot, Isolation

    ( a ) Wild-type FVB mice were injected with vehicle and the Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, DRGs were collected. DRG lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. ( b ) DRGs were collected from Wild-type and Yes1 −/− mice. The upper panel shows representative blots from experiments where DRG lysates were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. The lower panel shows western blot results from total DRG lysates showing that Yes1 is expressed in DRGs in the wild-type mice. ( c ) DRGs were collected from Wild-type FVB mice, followed by satellite cell isolation and culture. The primary satellite cells were then plated in six-well plates followed by oxaliplatin uptake assays in the presence of DMSO, lapatinib or Dasatinib (30 min). The graph represents relative oxaliplatin uptake as compared to DMSO group. * indicates a statistically significant difference compared with the DMSO group. ( d ) Sensitivity to cold associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.) as determined by a cold-plate test. The number of paw lifts or licks at baseline and following exposure to a temperature of −4 °C for 5 min at 24 h after drug administration was determined ( n =5). The graph represents relative percentage change in paw lifts/licks as compared with baseline values. ( e ) Mechanical allodynia associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.), as determined by a Von Frey Hairs test. The force required to induce paw withdrawal in grams (g) at baseline was measured following 24 h after drug administration ( n =5). The graph represents relative percentage change in paw withdrawal force as compared to baseline values. * indicates a statistically significant difference as compared with the baseline (untreated) values. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.
    Figure Legend Snippet: ( a ) Wild-type FVB mice were injected with vehicle and the Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, DRGs were collected. DRG lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. ( b ) DRGs were collected from Wild-type and Yes1 −/− mice. The upper panel shows representative blots from experiments where DRG lysates were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. The lower panel shows western blot results from total DRG lysates showing that Yes1 is expressed in DRGs in the wild-type mice. ( c ) DRGs were collected from Wild-type FVB mice, followed by satellite cell isolation and culture. The primary satellite cells were then plated in six-well plates followed by oxaliplatin uptake assays in the presence of DMSO, lapatinib or Dasatinib (30 min). The graph represents relative oxaliplatin uptake as compared to DMSO group. * indicates a statistically significant difference compared with the DMSO group. ( d ) Sensitivity to cold associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.) as determined by a cold-plate test. The number of paw lifts or licks at baseline and following exposure to a temperature of −4 °C for 5 min at 24 h after drug administration was determined ( n =5). The graph represents relative percentage change in paw lifts/licks as compared with baseline values. ( e ) Mechanical allodynia associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.), as determined by a Von Frey Hairs test. The force required to induce paw withdrawal in grams (g) at baseline was measured following 24 h after drug administration ( n =5). The graph represents relative percentage change in paw withdrawal force as compared to baseline values. * indicates a statistically significant difference as compared with the baseline (untreated) values. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Techniques Used: Injection, Western Blot, Cell Isolation

    Related Articles

    Recombinant:

    Article Title: A phosphotyrosine switch regulates organic cation transporters
    Article Snippet: .. Yes1 recombinant human protein was obtained from Life technologies (A15557). .. To purify OCT2 proteins, FLAG-tagged wild-type or mutant OCT2 constructs (described in the site-directed mutagenesis section) were subcloned into pT7CFE1-CHis plasmid (Thermo Fischer).



    Similar Products

    86
    Thermo Fisher yes1 recombinant human protein
    ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or <t>Yes1</t> plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.
    Yes1 Recombinant Human Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yes1+recombinant+human+protein/pmc04799362-192-0-7
    Average 86 stars, based on 1 article reviews
    yes1 recombinant human protein - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or Yes1 plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.

    Journal: Nature Communications

    Article Title: A phosphotyrosine switch regulates organic cation transporters

    doi: 10.1038/ncomms10880

    Figure Lengend Snippet: ( a ) Scheme depicting the assay conditions used in the primary siRNA kinome screen to identify an OCT2 phosphorylating kinase. HEK293-OCT2 cells were reverse transfected with the siRNA library and plated in 384-well plates, followed by incubation functional uptake and viability assays. ( b ) Positive hits from the primary screen. Only the tyrosine kinase hits (indicated in red) were used for secondary screens. ( c ) Schematic representation of secondary screens: deconvoluted screen using Dharmacon siRNA and Sigma siRNA screen. The siRNA that inhibited OCT2 function to at least 75% are indicated in red. ( d ) Hela-OCT2 cells were transfected with either wild-type or dasatinib resistant KDR, LYN or Yes1 plasmids and 24 h later, [ 14 C]-TEA uptake assays were performed in the presence or absence of varying concentrations of dasatinib. The graph represents relative OCT2 function ([ 14 C]-TEA uptake) as compared with DMSO group for each plasmid. ( e ) Hela-OCT2 cells were transfected with Sigma siRNA (scrambled control or Yes1) and 48 h later, OCT2 was immunoprecipitated to determine its tyrosine phosphorylation. Whole-cell lysate was used to confirm Yes1 knockdown.

    Article Snippet: Yes1 recombinant human protein was obtained from Life technologies (A15557).

    Techniques: Transfection, Incubation, Functional Assay, Plasmid Preparation, Immunoprecipitation

    ( a ) Schematic representation of Yes1 protein (upper panel) showing the SH3 domain. The lower panel shows the putative proline-rich SH3 binding sequence in OCT2. ( b ) Endogenous Yes1 was immunoprecipitated from Hela-Vector and Hela-OCT2 cell lysates using a mouse anti-Yes1 antibody, followed by western blot analysis with rabbit anti-FLAG and Yes1 antibodies. ( c ) Plasmids for OCT2 mutants were transiently transfected into Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM) or [ 14 C]-metformin (50 μM). The uptake levels were normalized to protein concentration in each group. The graph represents relative OCT2 function (TEA or metformin uptake) as compared to wild-type OCT2 transfected group. * indicates statistically significant as compared with wild-type group ( P <0.05, Student's t -test). ( d ) Hela cells were transiently transfected with indicated FLAG-tagged OCT2 constructs, followed by immunopreicipation with anti-FLAG antibodies and western blot analysis by FLAG and phosphotyrosine antibodies. ( e ) Proposed model of Yes1 and OCT2 interaction. ( f ) Plasmids for OCT1 and OCT3 mutants were transiently transfected in Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM). The uptake levels were normalized to protein concentration and the graph represents relative OCT2 function (TEA uptake) as compared with respective wild-type group. * indicates statistically significant as compared to wild-type group ( P <0.05, Student's t -test). All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Journal: Nature Communications

    Article Title: A phosphotyrosine switch regulates organic cation transporters

    doi: 10.1038/ncomms10880

    Figure Lengend Snippet: ( a ) Schematic representation of Yes1 protein (upper panel) showing the SH3 domain. The lower panel shows the putative proline-rich SH3 binding sequence in OCT2. ( b ) Endogenous Yes1 was immunoprecipitated from Hela-Vector and Hela-OCT2 cell lysates using a mouse anti-Yes1 antibody, followed by western blot analysis with rabbit anti-FLAG and Yes1 antibodies. ( c ) Plasmids for OCT2 mutants were transiently transfected into Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM) or [ 14 C]-metformin (50 μM). The uptake levels were normalized to protein concentration in each group. The graph represents relative OCT2 function (TEA or metformin uptake) as compared to wild-type OCT2 transfected group. * indicates statistically significant as compared with wild-type group ( P <0.05, Student's t -test). ( d ) Hela cells were transiently transfected with indicated FLAG-tagged OCT2 constructs, followed by immunopreicipation with anti-FLAG antibodies and western blot analysis by FLAG and phosphotyrosine antibodies. ( e ) Proposed model of Yes1 and OCT2 interaction. ( f ) Plasmids for OCT1 and OCT3 mutants were transiently transfected in Hela cells and 24 h later, uptake assays (15 min) were performed using [ 14 C]-TEA (2 μM). The uptake levels were normalized to protein concentration and the graph represents relative OCT2 function (TEA uptake) as compared with respective wild-type group. * indicates statistically significant as compared to wild-type group ( P <0.05, Student's t -test). All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Article Snippet: Yes1 recombinant human protein was obtained from Life technologies (A15557).

    Techniques: Binding Assay, Sequencing, Immunoprecipitation, Plasmid Preparation, Western Blot, Transfection, Protein Concentration, Construct

    ( a ) Wild-type FVB mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, the mice were euthanized and the kidneys were collected. Kidney tissue lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. ( b ) Male FVB mice were injected with dasatinib (15 mg kg −1 ) followed by pharmacokinetic analysis of dasatinib levels in the plasma. ( c ) Wild-type and Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later they were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.), followed by plasma collection at 5 min. The graph represents plasma TEA levels from n =5 mice per group. * indicates statistically significant as compared with wild-type vehicle group ( P <0.05, Student's t -test). ( d ) Isolated renal tubules were coincubated with dasatinib in the presence of the OCT2 substrate ASP (30 min), and relative uptake was measured compared with control group. ( e ) Wild-type FVB mice were injected with either control or Yes1 siRNA by hydrodynamic tail-vein injection (25 μg in 0.5 ml of PBS). Three days later, the mice were injected i.v. with a 0.2 mg kg −1 dose of [ 14 C]-TEA, and plasma levels of TEA were measured at 5 min ( n =5 mice per group). Kidneys were also collected to determine Yes1 knockdown. ( f ) Wild-type and Yes1 −/− mice ( n =5) were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.) and plasma levels of TEA were measured at 5 min. ( g ) Kidney tissue lysates from wild-type and Yes1 −/− were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Journal: Nature Communications

    Article Title: A phosphotyrosine switch regulates organic cation transporters

    doi: 10.1038/ncomms10880

    Figure Lengend Snippet: ( a ) Wild-type FVB mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, the mice were euthanized and the kidneys were collected. Kidney tissue lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. ( b ) Male FVB mice were injected with dasatinib (15 mg kg −1 ) followed by pharmacokinetic analysis of dasatinib levels in the plasma. ( c ) Wild-type and Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later they were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.), followed by plasma collection at 5 min. The graph represents plasma TEA levels from n =5 mice per group. * indicates statistically significant as compared with wild-type vehicle group ( P <0.05, Student's t -test). ( d ) Isolated renal tubules were coincubated with dasatinib in the presence of the OCT2 substrate ASP (30 min), and relative uptake was measured compared with control group. ( e ) Wild-type FVB mice were injected with either control or Yes1 siRNA by hydrodynamic tail-vein injection (25 μg in 0.5 ml of PBS). Three days later, the mice were injected i.v. with a 0.2 mg kg −1 dose of [ 14 C]-TEA, and plasma levels of TEA were measured at 5 min ( n =5 mice per group). Kidneys were also collected to determine Yes1 knockdown. ( f ) Wild-type and Yes1 −/− mice ( n =5) were injected with 0.2 mg kg −1 [ 14 C]-TEA (i.v.) and plasma levels of TEA were measured at 5 min. ( g ) Kidney tissue lysates from wild-type and Yes1 −/− were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phosphotyrosine and Oct2 antibodies. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Article Snippet: Yes1 recombinant human protein was obtained from Life technologies (A15557).

    Techniques: Injection, Western Blot, Isolation

    ( a ) Wild-type FVB mice were injected with vehicle and the Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, DRGs were collected. DRG lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. ( b ) DRGs were collected from Wild-type and Yes1 −/− mice. The upper panel shows representative blots from experiments where DRG lysates were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. The lower panel shows western blot results from total DRG lysates showing that Yes1 is expressed in DRGs in the wild-type mice. ( c ) DRGs were collected from Wild-type FVB mice, followed by satellite cell isolation and culture. The primary satellite cells were then plated in six-well plates followed by oxaliplatin uptake assays in the presence of DMSO, lapatinib or Dasatinib (30 min). The graph represents relative oxaliplatin uptake as compared to DMSO group. * indicates a statistically significant difference compared with the DMSO group. ( d ) Sensitivity to cold associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.) as determined by a cold-plate test. The number of paw lifts or licks at baseline and following exposure to a temperature of −4 °C for 5 min at 24 h after drug administration was determined ( n =5). The graph represents relative percentage change in paw lifts/licks as compared with baseline values. ( e ) Mechanical allodynia associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.), as determined by a Von Frey Hairs test. The force required to induce paw withdrawal in grams (g) at baseline was measured following 24 h after drug administration ( n =5). The graph represents relative percentage change in paw withdrawal force as compared to baseline values. * indicates a statistically significant difference as compared with the baseline (untreated) values. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Journal: Nature Communications

    Article Title: A phosphotyrosine switch regulates organic cation transporters

    doi: 10.1038/ncomms10880

    Figure Lengend Snippet: ( a ) Wild-type FVB mice were injected with vehicle and the Oct1/2 −/− mice were injected with either vehicle or dasatinib (15 mg kg −1 , p.o.) and 30 min later, DRGs were collected. DRG lysates were then used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. ( b ) DRGs were collected from Wild-type and Yes1 −/− mice. The upper panel shows representative blots from experiments where DRG lysates were used to immunoprecipitate endogenous Oct2 followed by western blot analysis by phospho-tyrosine and Oct2 antibodies. The lower panel shows western blot results from total DRG lysates showing that Yes1 is expressed in DRGs in the wild-type mice. ( c ) DRGs were collected from Wild-type FVB mice, followed by satellite cell isolation and culture. The primary satellite cells were then plated in six-well plates followed by oxaliplatin uptake assays in the presence of DMSO, lapatinib or Dasatinib (30 min). The graph represents relative oxaliplatin uptake as compared to DMSO group. * indicates a statistically significant difference compared with the DMSO group. ( d ) Sensitivity to cold associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.) as determined by a cold-plate test. The number of paw lifts or licks at baseline and following exposure to a temperature of −4 °C for 5 min at 24 h after drug administration was determined ( n =5). The graph represents relative percentage change in paw lifts/licks as compared with baseline values. ( e ) Mechanical allodynia associated with a single dose of oxaliplatin (40 mg kg −1 ) in wild-type mice pretreated with vehicle or dasatinib (15 mg kg −1 , p.o.), as determined by a Von Frey Hairs test. The force required to induce paw withdrawal in grams (g) at baseline was measured following 24 h after drug administration ( n =5). The graph represents relative percentage change in paw withdrawal force as compared to baseline values. * indicates a statistically significant difference as compared with the baseline (untreated) values. All experimental values are presented as mean±s.e.m. The height of error bar=1 s.e.

    Article Snippet: Yes1 recombinant human protein was obtained from Life technologies (A15557).

    Techniques: Injection, Western Blot, Cell Isolation